{
  "pmcid": "10338899",
  "sha256": "acebbffae20b1652a1b478ab9a4f4da374fdda4ab7d4cbc9b7e0398891aeda86",
  "timestamp_utc": "2025-11-09T21:52:58.098111+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.346296296296298,
    "reading_ease": 30.590833333333364,
    "word_count": 216
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial of Early Versus Conventional Adjuvant Chemotherapy in Stage III Colon Cancer"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "A multicentre, randomised (1:1), open-label, phase III trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were adults with histologically confirmed stage III colon cancer who underwent radical surgery."
      },
      "Intervention": {
        "score": 2,
        "evidence": "EAC was administered between postoperative days 10 and 14, while CAC was administered between days 24 and 28."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate the safety and oncological efficacy of early adjuvant chemotherapy (EAC) compared to conventional adjuvant chemotherapy (CAC) in patients with stage III colon cancer."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary endpoint was 3-year disease-free survival (DFS)."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a web-based platform with allocation concealment."
      },
      "Blinding": {
        "score": 3,
        "evidence": "open-label"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Between 9 September 2011 and 6 March 2020, 443 patients were randomised, with 209 in the EAC arm and 214 in the CAC arm."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "The intention-to-treat analysis included 423 patients."
      },
      "Result_Outcome": {
        "score": 1,
        "evidence": "There was no significant difference in overall toxicity (28.1% in EAC vs. 28.2% in CAC, P = 0.244) or quality of life between the groups."
      },
      "Harms": {
        "score": 1,
        "evidence": "There was no significant difference in overall toxicity (28.1% in EAC vs. 28.2% in CAC, P = 0.244)"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "The trial was registered at ClinicalTrials.gov (NCT01460589)."
      },
      "Funding": {
        "score": 1,
        "evidence": "This trial was funded by the participating institutions."
      }
    },
    "total_score": 23,
    "max_score": 25
  }
}